Chembio Diagnostics (CEMI -1.3%) says it's entered into a six-month follow-on, milestone-based...


Chembio Diagnostics (CEMI -1.3%) says it's entered into a six-month follow-on, milestone-based development agreement with a private contracting organization to implement and provide technical oversight relating to pandemic preparedness on behalf of the US Centers for Disease Control and Prevention, for a rapid, POC influenza immunity test utilizing CEMI's patented Dual Path Platform technology.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs